Navigation Links
New Study Shows Tapentadol Extended Release (ER) May Significantly Reduce Average Pain Intensity for Diabetic Patients Suffering From Painful Peripheral Neuropathy
Date:1/28/2011

and osteoarthritic pain.  Also in the current study, the mean percentage of days on treatment with tapentadol ER that patients experienced nausea, vomiting, and constipation, respectively, was relatively low in both the open-label (8.8, 2.2 and 5.4 percent) and, particularly, in the double-blind (2.9, 1.0 and 1.9 percent) phases.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) and Grunenthal GmbH, conducted this study, which J&JPRD has included as part of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol ER tablets for the management of moderate to severe chronic pain in patients 18 years of age or older. The FDA currently is reviewing this application and, if approved, PriCara®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., will market tapentadol ER in the United States.

About tapentadolTapentadol is a centrally acting oral analgesic that binds to mu-opioid receptors and inhibits norepinephrine re-uptake. Although the exact mechanism of action is not known, these two mechanisms, which affect established pain pathways, are thought to be responsible for pain relief with tapentadol. The tapentadol molecule is classified as Schedule II of the Controlled Substances Act.

NUCYNTA® (tapentadol immediate release) was approved by the FDA on November 20, 2008, and is available by prescription only for the relief of moderate to severe acute pain in patients 18 years of age or older. On December 1, 2009, J&JPRD submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tapentadol extended release (ER) tablets for the management of moderate to severe chronic pain in patients 18 years of age or older [http://www.jnj.com/connect/news/product/20091201_200000]. The tapentadol ER tablet formulation is designed to provide a high degree of mecha
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sanofi-aventis Reports Top-line Results from Phase III Study with Iniparib (BSI-201) in Metastatic Triple-Negative Breast Cancer
2. US Army Study Shows STB Lifesaving Technologys® FAST® Dressing Superior to the Most Effective Currently Available Agents for Controlling Arterial Bleeding
3. Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study
4. Surgeons at University of California San Diego Perform 1st TRAM Flap Procedure in an International Multi-Center Study Using TIGR® Matrix Surgical Mesh, the Worlds 1st Long-Term Resorbable Mesh
5. Generex to Increase Patient Enrollment of its Phase II Breast Cancer Vaccine Study
6. R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia
7. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
8. NIH-Funded Study Is First to Demonstrate Increased Long-Term Survival With Favorable Neurologic Function Among Patients Receiving CPR Using ACSI ResQPump® and ResQPOD® CPR Devices
9. CVS Caremark Study Evaluates Which Pharmacy Channel Consumers Choose When Given Choice of Mail or Retail Prescriptions
10. New Study on HIV/AIDS Redefines the Size, Scale, and Scope of Epidemic
11. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... , July 21, 2014 Decision Resources ... (AD) therapies will more than triple, reaching nearly ... forecasted launch of the first disease-modifying therapies (DMTs), ... these novel premium-priced agents—which include the anti-beta-amyloid monoclonal ... well as the BACE inhibitor MK-8931 (Roche/Chugai/MorphoSys)—will earn ...
(Date:7/21/2014)... ALBANY, New York , July 21, 2014 /PRNewswire/ ... market report published by Transparency Market Research "E-Clinical Solution ... and Forecast, 2014 - 2020," the global microfluidic device ... and is expected to grow at a CAGR of ... value of USD 6,515.3 million in 2020. ...
(Date:7/21/2014)...  PowerVision, Inc., a medical device company developing ... announced that Douglas D. Koch , M.D., ... and Professor of Ophthalmology, at Baylor College of ... As a recipient of several ... Lifetime Achievement award, Koch will join the distinguished ...
Breaking Medicine Technology:The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 2The Alzheimer's Disease Market Is Forecast to Reach Nearly $12 Billion by 2023, Following the Projected Launch of the First Disease-Modifying Therapies 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 2PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 3PowerVision Appoints Ophthalmology Thought Leader Douglas D. Koch, M.D. to its Scientific Advisory Board 4
... 13, 2011  GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based ... fight Human Immunodeficiency Virus (HIV) infections, announced that the ... clinical trial for the Company,s HIV/AIDS therapeutic vaccine.  This ... the treatment of persons who are HIV infected. ...
... Masimo (NASDAQ: MASI ) ... Acoustic Respiration Rate (RRa™) was presented at the ... Graduate Assembly (PGA) Meeting in New York City. ... the positive clinical outcomes and patient safety impact of Masimo,s ...
Cached Medicine Technology:GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 2GeoVax Labs' First Patient Inoculated in Phase 1/2 Clinical Trial for HIV/AIDS Therapeutic Vaccine 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 2New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 3New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 4New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology 5
(Date:7/22/2014)... Hope For The Warriors® is excited to ... staff. This addition comes in tandem with new office ... The Warriors® is a national nonprofit organization that assists ... the fallen who have sustained physical and psychological wounds ... will support programs within Career Transition & Education. He ...
(Date:7/22/2014)... Garland’s new Energizer BK ... used as a flood coat over new and existing ... premium restoration material. It provides natural resistance to moisture, ... reducing life-cycle costs. Energizer BK is specially formulated with ... resistance in addition to superior strength and flexibility. ...
(Date:7/22/2014)... July 22, 2014 The hair ... are now offering robotic assisted laser therapy and ... solutions for men and women suffering from hair ... they now offer Follicular Unit Extraction (FUE) procedures ... robot. With this new technology, their doctors use ...
(Date:7/21/2014)... fastest-growing high school sports in the United States, with ... game. The growing participation numbers, however, mean that more ... in lacrosse practice and competition. , In a study ... Sports Medicine and available in an upcoming print ... Policy at Nationwide Children,s Hospital and the Colorado School ...
(Date:7/21/2014)... As reported by CBS Local Pittsburgh in the article ... (7/15), thrill-seeking participants raised $100,000 to raise drug abuse ... Philly. 100 people, including some well-known local news reporters, ... Hotel. Some of the participants shared stories of their ... son killed himself after a long battle with addiction. ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Builds on Staff and Office Space in Chicago to Support Career Transition for Vets 2Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3
... --MinuteClinic Provides Quality and Convenience Close to Home and the ... ... Alliance With Integris Health--, OKLAHOMA CITY, Sept. 7 Quick, convenient, ... opening of a,MinuteClinic health care center at the CVS/pharmacy store in Moore ...
... pulmonary embolisma potential life-threatening blockage in a lung arteryshould ... than a CT (computed tomography) angiogram, conclude authors in ... Medicine. , A V/Q scan can be the first ... a pulmonary embolism, noted H. Dirk Sostman, a professor ...
... School at the University of Warwick reveals that womens health ... , The researchers looked at men and women sleeping ... see if their risk of having hypertension was any higher ... more of sleep a night. Among other problems increased hypertension ...
... Blue Shield in Indiana for its Members, INDIANAPOLIS, ... and,M-Plan, Inc., an Indiana-based managed care organization, announced today,that ... of Indiana as,the insurer of choice for its members ... WellPoint and M-Plan have entered into an,agreement that ensures ...
... KING OF PRUSSIA, PA, Sept. 7 /PRNewswire-FirstCall/ - ... discovery and development,solutions, has won the Good Clinical ... that best promotes access to new medicines. This,award ... awards introduced this year to,recognize excellence in clinical ...
... N.J., Sept. 6 Wyeth (NYSE: WYE ... that the United States,District Court for the District ... a preliminary injunction against Teva Pharmaceuticals USA, Inc.,and ... of a generic,version of PROTONIX(R) (pantoprazole sodium) prior ...
Cached Medicine News:Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 2Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 3Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 4Health News:An Innovation in Health Care Opens at a CVS/pharmacy Store in the Oklahoma City Region 5Health News:Nuclear medicine approach can be first choice for excluding pulmonary embolism in young women 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 2Health News:WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana 3Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 2Health News:Wyeth and Nycomed Announce Court Denial of Preliminary Injunction 3
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... Smith & Nephew ECTRA II systems permit ... carpal tunnel ligament endoscopically, allowing access via ... while minimizing endoscopic lens fogging with good ... complete visualization and control. ECTRA knives permit ...
Medicine Products: